华熙生物_初步看法_2025 年净利润不及预期，主要因医美产品销售疲软；卖出

26 August 2025 | 10:28PM HKT Bloomage Biotechnology Corp. (688363.SS): First Take: 2Q25 NI miss mainly on weaker medical aesthetics product sales; Sell Bloomage reported 2Q25 results after market close on Aug 26. 2Q25 NI (+21% yoy) missed expectations coming in 52%/43% lower than GSe/VA consensus, due to 1) 29%/22% lower sales (-18% yoy) vs. GSe/VA consensus driven by weak medical devices/raw materials sales; and 2) lower GPM likely due to step up discount, and lower-than-expected mix from high margin MA bu ...